Rwanda Biomedical Centre and Pfizer Forge Groundbreaking Research Collaboration
In a landmark move, Rwanda Biomedical Centre (RBC) and Pfizer entered a collaborative agreement to access and research information. This unique framework will allow the two organizations to work together in sharing knowledge, expertise, and resources, with the aim of deepening the understanding of Rwanda patient population and the impact of Pfizer medicines and vaccines.
RBC Director General, Professor Claude Mambo Muvunyi, welcomed the collaborative efforts between the two organizations as a key milestone toward Rwanda’s vision of building a resilient healthcare system.
“This agreement marks a significant step forward in advancing clinical research in Rwanda with the ultimate goal of improving patient outcomes and strengthening our healthcare system”, he said.
This first-of-its-kind research framework is expected to enhance Rwandan public health goals and enable world-class evidence generation across multiple therapeutic areas that can benefit Ministries of Health, healthcare providers and patients in Rwanda and beyond.
Dr. Tamas Andras Koncz, Medical Lead for Accord for a Healthier World added: “To enable sustainable access solutions, we need to better understand both the health and health economic impacts of our medicines and vaccines. We are fully committed to patient well-being and the safe and effective use of our medicines and vaccines made available through the Accord. This peer-to-peer collaboration offers an important opportunity for evidence generation to further confirm the safety and efficacy of our products within the Rwandan population and can help to generate impact data that we have never before been able to measure to support Rwanda in long-term planning for its healthcare priorities.”
RBC Director General, Professor Claude Mambo Muvunyi together with Dr. Tamas Andras Koncz, Medical Lead for Accord for a Healthier World